Liver Disease in Cystic Fibrosis: an Update

被引:28
作者
Parisi, Giuseppe Fabio [1 ]
Di Dio, Giovanna [1 ]
Franzonello, Chiara [1 ]
Gennaro, Alessia [1 ]
Rotolo, Novella [1 ]
Lionetti, Elena [1 ]
Leonardi, Salvatore [1 ]
机构
[1] Univ Catania, Dept Med & Pediat Sci, Bronchopneumol & Cyst Fibrosis Unit, Catania, Italy
关键词
Cystic Fibrosis; Liver Disease; Mutation; TRANSMEMBRANE CONDUCTANCE REGULATOR; HEPATIC STELLATE CELLS; HEPATOBILIARY DISEASE; RISK-FACTORS; CHILDREN; TRANSPLANTATION; MANIFESTATIONS; ULTRASOUND; MANAGEMENT; EXPRESSION;
D O I
10.5812/hepatmon.11215
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Context: Cystic fibrosis (CF) is the most widespread autosomal recessive genetic disorder that limits life expectation amongst the Caucasian population. As the median survival has increased related to early multidisciplinary intervention, other manifestations of CF have emergedespecially for the broad spectrum of hepatobiliary involvement. The present study reviews the existing literature on liver disease in cystic fibrosis and describes the key issues for an adequate clinical evaluation and management of patients, with a focus on the pathogenetic, clinical and diagnostic-therapeutic aspects of liver disease in CF. Evidence Acquisition: A literature search of electronic databases was undertaken for relevant studies published from 1990 about liver disease in cystic fibrosis. The databases searched were: EMBASE, PubMed and Cochrane Library. Results: CF is due to mutations in the gene on chromosome 7 that encodes an amino acidic polypeptide named CFTR (cystic fibrosis transmembrane regulator). The hepatic manifestations include particular changes referring to the basic CFTR defect, iatrogenic lesions or consequences of the multisystem disease. Even though hepatobiliary disease is the most common non-pulmonary cause ofmortalityin CF (the third after pulmonary disease and transplant complications), only about the 33%ofCF patients presents clinically significant hepatobiliary disease. Conclusions: Liver disease will have a growing impact on survival and quality of life of cystic fibrosis patients because a longer life expectancy and for this it is important its early recognition and a correct clinical management aimed atdelaying the onset of complications. This review could represent an opportunity to encourage researchers to better investigate genotype-phenotype correlation associated with the development of cystic fibrosis liver disease, especially for non-CFTR genetic polymorphisms, and detect predisposed individuals. Therapeutic trials are needed to find strategies of fibrosis prevention and to avoid its progression prior to development its related complications.
引用
收藏
页数:8
相关论文
共 75 条
  • [1] Gastrointestinal manifestations of cystic fibrosis: Radiologic-pathologic correlation
    Agrons, GA
    Corse, WR
    Markowitz, RI
    Suarez, ES
    Perry, DR
    [J]. RADIOGRAPHICS, 1996, 16 (04) : 871 - 893
  • [2] Hepatobiliary manifestations of cystic fibrosis in children:: correlation of CT and US findings
    Akata, D
    Akhan, O
    Özcelik, U
    Özmen, MN
    Oguzkurt, L
    Haliloglu, M
    Göcmen, A
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2002, 41 (01) : 26 - 33
  • [3] GALLSTONES IN CYSTIC-FIBROSIS - A CRITICAL REAPPRAISAL
    ANGELICO, M
    GANDIN, C
    CANUZZI, P
    BERTASI, S
    CANTAFORA, A
    DESANTIS, A
    QUATTRUCCI, S
    ANTONELLI, M
    [J]. HEPATOLOGY, 1991, 14 (05) : 768 - 775
  • [4] Toll-Like Receptor Signaling and Liver Fibrosis
    Aoyama, Tomonori
    Paik, Yong-Han
    Seki, Ekihiro
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2010, 2010
  • [5] Genetic Modifiers of Liver Disease in Cystic Fibrosis
    Bartlett, Jaclyn R.
    Friedman, Kenneth J.
    Ling, Simon C.
    Pace, Rhonda G.
    Bell, Scott C.
    Bourke, Billy
    Castaldo, Giuseppe
    Castellani, Carlo
    Cipolli, Marco
    Colombo, Carla
    Colombo, John L.
    Debray, Dominique
    Fernandez, Adriana
    Lacaille, Florence
    Macek, Milan, Jr.
    Rowland, Marion
    Salvatore, Francesco
    Taylor, Christopher J.
    Wainwright, Claire
    Wilschanski, Michael
    Zemkova, Dana
    Hannah, William B.
    Phillips, M. James
    Corey, Mary
    Zielenski, Julian
    Dorfman, Ruslan
    Wang, Yunfei
    Zou, Fei
    Silverman, Lawrence M.
    Drumm, Mitchell L.
    Wright, Fred A.
    Lange, Ethan M.
    Durie, Peter R.
    Knowles, Michael R.
    Clancy, J. P.
    Sindel, L. J.
    Roberts, D. M.
    Roberts, V.
    Radford, P. J.
    Argel, N.
    Morgan, W. J.
    Douthit, J. L.
    Schellhase, D. E.
    Anderson, P.
    Taggart, A.
    Morrissey, B.
    Platzker, A. C. G.
    Woo, M. S.
    Fukushima, L.
    Hsu, E.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (10): : 1076 - 1083
  • [6] Castaldo G, 2001, AM J MED GENET, V98, P294, DOI 10.1002/1096-8628(20010201)98:4<294::AID-AJMG1097>3.0.CO
  • [7] 2-K
  • [8] Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
    Castellani, C.
    Cuppens, H.
    Macek, M., Jr.
    Cassinian, J. J.
    Kerern, E.
    Durie, P.
    Tullis, E.
    Assael, B. M.
    Bombieri, C.
    Brown, A.
    Casals, T.
    Claustres, M.
    Cutting, G. R.
    Dequeker, E.
    Dodge, J.
    Doull, I.
    Farrell, P.
    Ferec, C.
    Girodon, E.
    Johannesson, M.
    Kerem, B.
    Knowles, M.
    Munck, A.
    Pignatti, P. F.
    Radojkovic, D.
    Rizzotti, P.
    Schwarz, M.
    Stuhnnann, M.
    Tzetis, M.
    Zielenski, J.
    Elborn, J. S.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (03) : 179 - 196
  • [9] LOCALIZATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN HUMAN BILE-DUCT EPITHELIAL-CELLS
    COHN, JA
    STRONG, TV
    PICCIOTTO, MR
    NAIRN, AC
    COLLINS, FS
    FITZ, JG
    [J]. GASTROENTEROLOGY, 1993, 105 (06) : 1857 - 1864
  • [10] ANALYSIS OF RISK-FACTORS FOR THE DEVELOPMENT OF LIVER-DISEASE ASSOCIATED WITH CYSTIC-FIBROSIS
    COLOMBO, C
    APOSTOLO, MG
    FERRARI, M
    SEIA, M
    GENONI, S
    GIUNTA, A
    SERENI, LP
    [J]. JOURNAL OF PEDIATRICS, 1994, 124 (03) : 393 - 399